Informative study designs to identify true parameter-covariate relationships

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 36, Issue 2, 2009, Pages 147-163

  Han, Phey Yen ^a   Kirkpatrick, Carl M J ^a   Green, Bruce ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Model Answers Pty Ltd   (Australia)

Author keywords

Covariate selection; NONMEM; Population modelling; Study design

Indexed keywords

ANALYTICAL ERROR; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; HISTOGRAM; LEAN BODY WEIGHT; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; METHODOLOGY; PARAMETERS OF MEASUREMENT AND ANALYSIS; PRIORITY JOURNAL; PROBABILITY; SIMULATION; STRATIFICATION;

COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; PHARMACOKINETICS; RESEARCH DESIGN;

EID: 67349255204     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-009-9115-y     Document Type: Article

References (27)

1. R Miller W Ewy BW Corrigan D Ouellet D Hermann KG Kowalski 2005 How modeling and simulation have enhanced decision making in new drug development J Pharmacokinet Pharmacodyn 32 185 197 10.1007/s10928-005-0074-7 (Pubitemid 41712739)
2. Food and Drug Administration (1999) Guidance for industry: population pharmacokinetics. U.S. Department of Health and Human Services, Rockville, MD
3. R Gieschke J-L Steimer 2000 Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development Eur J Drug Metab Pharmacokinet 25 49 58
4. JY Chien S Friedrich MA Heathman DP de Alwis V Sinha 2005 Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation AAPS J 7 E544 E559 10.1208/aapsj070355 (Pubitemid 41631734)
5. RL Lalonde KG Kowalski MM Hutmacher W Ewy DJ Nichols PA Milligan 2007 Model-based drug development Clin Pharmacol Ther 82 21 32 10.1038/sj.clpt. 6100235 (Pubitemid 46950619)
6. SB Duffull T Waterhouse J Eccleston 2005 Some considerations on the design of population pharmacokinetic studies J Pharmacokinet Pharmacodyn 32 441 457 10.1007/s10928-005-0034-2 (Pubitemid 41738435)
7. NHG Holford HC Kimko JPR Monteleone CC Peck 2000 Simulation of clinical trials Annu Rev Pharmacol Toxicol 40 209 234 10.1146/annurev.pharmtox.40.1.209 (Pubitemid 30340680)
8. J Ribbing AC Hooker EN Jonsson 2008 Non-bayesian knowledge propagation using model-based analysis of data from multiple clinical studies J Pharmacokinet Pharmacodyn 35 117 137 10.1007/s10928-007-9079-8
9. PO Maitre M Bührer D Thomson DR Stanski 1991 A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam J Pharmacokinet Biopharm 19 377 384 10.1007/BF01061662
10. JW Mandema D Verotta LB Sheiner 1992 Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects J Pharmacokinet Biopharm 20 511 528 10.1007/BF01061469 (Pubitemid 23034413)
11. EN Jonsson MO Karlsson 1998 Automated covariate model building within NONMEM Pharm Res 15 1463 1468 10.1023/A:1011970125687 (Pubitemid 28427937)
12. KG Kowalski MM Hutmacher 2001 Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test J Pharmacokinet Pharmacodyn 28 253 275 10.1023/A:1011579109640
13. S McLeay G Morrish CMJ Kirkpatrick B Green 2007 Lean bodyweight as a descriptor for propofol clearance AAPS J 9 W4527
14. FE Harrell Jr KL Lee DB Mark 1996 Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 361 387 10.1002/(SICI)1097-0258(19960229)15: 4<361::AID-SIM168>3.0.CO;2-4 (Pubitemid 26072233)
15. J Ribbing EN Jonsson 2004 Power, selection bias and predictive performance of the population pharmacokinetic covariate model J Pharmacokinet Pharmacodyn 31 109 134 10.1023/B:JOPA.0000034404.86036.72 (Pubitemid 38932393)
16. PY Han SB Duffull CMJ Kirkpatrick B Green 2007 Dosing in obesity: a simple solution to a big problem Clin Pharmacol Ther 82 505 508 10.1038/sj.clpt.6100381
17. SB Duffull MJ Dooley B Green SG Poole CMJ Kirkpatrick 2004 A standard weight descriptor for dose adjustment in the obese patient Clin Pharmacokinet 43 1167 1178 10.2165/00003088-200443150-00007 (Pubitemid 40013182)
18. S Retout F Mentré R Bruno 2002 Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics Stat Med 21 2623 2639 10.1002/sim.1041
19. S Janmahasatian SB Duffull S Ash LC Ward NM Byrne B Green 2005 Quantification of lean bodyweight Clin Pharmacokinet 44 1051 1065 10.2165/00003088-200544100-00004
20. EI Ette PJ Williams 2004 Population pharmacokinetics I: background, concepts and models Ann Pharmacother 38 1702 1706 10.1345/aph.1D374
21. T Podranski T Bouillon PM Schumacher A Taguchi DI Sessler A Kurz 2005 Compartmental pharmacokinetics of dantrolene in adults: do malignant hyperthermia association dosing guidelines work? Anesth Analg 101 1695 1699 10.1213/01.ANE.0000184184.40504.F3
22. L Aarons LP Balant F Mentré PL Morselli M Rowland J-L Steimer 1996 Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies Eur J Clin Pharmacol 49 251 254 10.1007/BF00226323
23. Food and Drug Administration (1998) Guidance for industry: pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labelling. U.S. Department of Health and Human Services, Rockville, MD
24. MO Karlsson RM Savic 2007 Diagnosing model diagnostics Clin Pharmacol Ther 82 17 20 10.1038/sj.clpt.6100241
25. Karlsson MO, Holford NHG (2008) A tutorial on visual predictive checks. PAGE 17 Abstr 1434, www.page-meeting.org/?abstract=1434
26. B Green SB Duffull 2003 Development of a dosing strategy for enoxaparin in obese patients Br J Clin Pharmacol 56 96 103 10.1046/j.1365-2125.2003.01849.x
27. U Wählby EN Jonsson MO Karlsson 2001 Assessment of actual significance levels for covariate effects in NONMEM J Pharmacokinet Pharmacodyn 28 231 252 10.1023/A:1011527125570